WS #16510
The healthcare and financial sectors delivered solid earnings results, providing a stabilizing force in the market. Merck (MRK) crushed Q3 estimates with $18.1 billion in sales, driven by the continued surge in Keytruda and Gardasil, and raised its full-year outlook. Bristol Myers Squibb (BMY) reported a 7% revenue increase and raised its 2026 guidance despite an R&D charge. In finance, Freddie Mac reported Q3 revenue of $6.8 billion, beating estimates by $970 million, highlighting the resilience of the mortgage market despite higher rates.
Pharma and Financial Earnings
The healthcare and financial sectors delivered solid earnings results, providing a stabilizing force in the market. Merck (MRK) crushed Q3 estimates with $18.1 billion in sales, driven by the continued surge in Keytruda and Gardasil, and raised its full-year outlook. Bristol Myers Squibb (BMY) reported a 7% revenue increase and raised its 2026 guidance despite an R&D charge. In finance, Freddie Mac reported Q3 revenue of $6.8 billion, beating estimates by $970 million, highlighting the resilience of the mortgage market despite higher rates.